Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin plus once-daily evening metformin versus twice-daily metformin in treatment-naive type 2 diabetes
2011-002276-16Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Linagliptin + metformin once daily evening with Metformin twice daily (2 arms). Primary endpoint: Change from baseline in HbA1c after 14 weeks of treatment. Started Sep 2011; status: completed.
02
Drugs
linagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-002276-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002276-16.